This content is from: Features

Indian patentability refined, post-Glivec

The Novartis decision on April 1 2013 turned the spotlight on section 3(d) of India’s Patent Act. A year on, Meenakshi Khurana looks at how this doctrine, along with obviousness standards, have been interpreted in recent cases

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial